A detailed study of sulfonate ester formation and solvolysis reaction rates and application toward establishing sulfonate ester control in pharmaceutical manufacturing processes

Organic Process Research and Development

Volumn 14, Issue 4, 2010, Pages 999-1007

  Teasdale, Andrew ^a   Delaney, Edward J ^b   Eyley, Stephen C ^a   Jacq, Karine ^c   Taylor Worth, Karen ^d   Lipczynski, Andrew ^d   Hoffmann, Wilfried ^d   Reif, Van ^e   Elder, David P ^f   Facchine, Kevin L ^g   Golec, Simon ^h   Schulte Oestrich, Rolf ⁱ   Sandra, Pat ^c   David, Frank ^c  

^a ASTRAZENECA   (United Kingdom)

^b Reaction Science Consulting   (United States)

^c Research Institute for Chromatography   (Belgium)

^d PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^e MERCK RESEARCH LABORATORIES   (United States)

^f GLAXOSMITHKLINE   (United Kingdom)

^g GLAXOSMITHKLINE   (United States)

^h PFIZER INC   (United States)

ⁱ F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVE PHARMACEUTICAL INGREDIENTS; DETAILED KINETICS; HIGH CONCENTRATION; KINETIC MODELS; MECHANISTIC STUDIES; PHARMACEUTICAL FIRMS; PHARMACEUTICAL MANUFACTURING; PROCESS DEVELOPMENT; PROTONATED; PROTONATING; REGULATORY AGENCIES; SULFONATE ANION; SULFONATE ESTERS; SULFONIC ACID; TRACE LEVEL;

DRUG PRODUCTS; ESTERIFICATION; ORGANIC POLYMERS; PHOSPHORIC ACID; PROCESS CONTROL; REACTION RATES; SALTS; SOLVENTS;

ESTERS;

EID: 77955367912     PISSN: 10836160     EISSN: 1520586X     Source Type: Journal    
DOI: 10.1021/op900301n     Document Type: Article

References (11)

1. Coordination Group for Mutual Recognition-Human committee (CMDh), Request to Assess the Risk of Occurrence of Contamination with Mesilate Esters and Other Related Compounds in Pharmaceuticals, EMEA/CMDh/ 98694/2008; European Medicines Agency: London, 27th February 2008.
2. Teasdale, A.; Eyley, S.; Delaney, E.; Jacq, K.; Taylor-Worth, K.; Lipczynski, A.; Reif, V.; Elder, D.; Facchine, K.; Golec, S.; Oestrich, R. S.; Sandra, P.; David, F. Org. Process Res. Dev. 2009, 13, 429-433
3. Jacq, K.; Delaney, E.; Teasdale, A.; Eyley, S.; Taylor-Worth, K.; Lipczynski, A.; Reif, V.; Elder, D.; Facchine, K.; Golec, S.; Oestrich, R. S.; Sandra, P.; David, F. J. Pharm. Biomed. Anal. 2008, 48, 1339-1344
4. Elder, D. P.; Teasdale, A.; Lipczynski, A. J. Pharm. Biomed. Anal. 2008, 46, 1-8
5. Paul, M. A.; Long, F. A. Chem. Rev. 1957, 57 (1) 1-45
6. Jorgenson, M. J.; Hartter, D. R. J. Am. Chem. Soc. 1963, 85 (7) 878-883
7. Lee, D. G.; Cameron, R. J. Am. Chem. Soc. 1971, 93 (19) 4724-4728
8. Farcasiu, D.; Ghenciu, A. Prog. Nucl. Magn. Spectrosc. 1969, 29, 129-168
9. Paul, R. C.; Kapila, V. P.; Kumar, R.; Sharma, S. K. J. Inorg. Nucl. Chem. 1981, 43 (1) 171-172
10. Weston, R. E.; Ehrenson, S.; Heinzinger, K. J. Am. Chem. Soc. 1967, 89 (3) 481-486
11. Gerber, C.; Toelle, H.-G. Toxicol. Lett. 2009, 1903, 248-253